A5083038998- Multiple Myeloma Research and Treatments
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Synthesis and Biological Evaluation
- Health Systems, Economic Evaluations, Quality of Life
- Protein Degradation and Inhibitors
- Pharmaceutical Practices and Patient Outcomes
- Hedgehog Signaling Pathway Studies
- Cutaneous Melanoma Detection and Management
- Opioid Use Disorder Treatment
- Cancer Treatment and Pharmacology
- Chemotherapy-related skin toxicity
- Lysosomal Storage Disorders Research
- Polyomavirus and related diseases
- Clostridium difficile and Clostridium perfringens research
- Nausea and vomiting management
- Diabetes Management and Research
- Peptidase Inhibition and Analysis
- Trypanosoma species research and implications
- Lipoproteins and Cardiovascular Health
- Microscopic Colitis
- Organ Donation and Transplantation
- Cancer and Skin Lesions
- Pharmaceutical Economics and Policy
- Poisoning and overdose treatments
Regeneron (United States)
2022-2025
Open Health Systems Laboratory
2022-2023
Access to Wholistic and Productive Living Institute
2023
Pharmerit (United States)
2018-2021
Prevea Health
2013-2018
Virginia Commonwealth University
2012-2013
Health Economics and Outcomes Research (United Kingdom)
2012
BackgroundRates of opioid poisoning and related mortality have increased substantially over the past decade. Although previous studies measured costs misuse abuse, specifically to not been quantified. This study quantifies economic burden in United States help evaluate case for efforts reverse or prevent its associated morbidity mortality.
Aims To quantify patient preferences for attributes of novel treatments triple-class–exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM).
The management of Clostridium difficile infection (CDI) among hospitalized patients is costly, and ongoing payment reform compelling hospitals to reduce its burden. To assess the impact CDI on mortality, hospital costs, healthcare use, Medicare payments for beneficiaries who were discharged with listed as a secondary International Classification Diseases, Ninth Revision, Clinical Modification claim diagnosis.Data analyzed from 2009 2010 5% random sample Standard Analytic Files beneficiary...
The objective of this study is to estimate the cost-effectiveness KTE-X19 versus standard care (SoC) in treatment relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients from a US healthcare perspective.A three-state partitioned-survival model (pre-progression, post-progression, and death) with cycle length 1 month was used extrapolate progression-free overall survival (OS) over lifetime horizon. Due long tail OS curve, modeled applying mixture-cure methodology, using assumption that...
Study Objectives To determine the proportion of hospitalized adults with hospital‐onset C lostridium difficile infection ( CDI ) who continued to receive concomitant non‐CDI antibacterial agents, characterize therapy that these patients received before and after diagnosis CDI, compare hospital outcomes between those did not have their previous discontinued diagnosis. Design Retrospective cohort study. Data Source Drug use administrative discharge data from 42 United States academic medical...
Aim Gaucher disease (GD) is a rare autosomal recessive condition. Type 1 GD (GD1) the most prevalent form of in Western countries; enzyme replacement therapy (ERT) treatment option for patients with GD1. To understand economic value GD1 ERT velaglucerase alfa, budget impact model (BIM) was developed from United States (US) payer perspective.Methods We estimated alfa 10-million-member US health plan by comparing annual total costs between scenario using current uptake to projected increased...
Prior to the Food and Drug Administration approval of cemiplimab in 2018, median overall survival (OS) for adult patients with advanced CSCC receiving systemic therapy was approximately 8 15 months. Limited real-world data are available on this indication US.
Abstract Background A phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor (HHI) therapy due to intolerance previous HHI therapy, disease progression while receiving or having better than stable on after 9 months. Here, health‐related quality of life (QoL) this patient population is reported. Methods Adult mBCC treated intravenous at dose...
Pen needles are an important component of insulin delivery among patients with diabetes, but not universally covered in China. We compared clinical and economic characteristics insulin-dependent China who have some level pen needle (PN) reimbursement to those no PN reimbursement. A cross-sectional study was conducted 400 users Type 1 or 2 diabetes treated outpatient endocrinology units four large tertiary care hospitals Nanjing, Chongqing, Beijing Zhengzhou. Demographics, medical history,...
The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines secondary prevention. We aimed assess whether initiating statin treatment CAD with baseline LDL-C 70–100 Taiwan could be cost-effective. A Markov model was developed simulate a hypothetical cohort of 90 mg/dL. incidence and recurrence MI stroke related specific levels as well the effect, mortality rate, health...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Frontline treatment for multiple myeloma (MM) often utilizes combinations of 2–4 active drugs, including an immunomodulatory drug, a proteasome inhibitor (PI), anti-CD38 antibody (mAb). However, relapse remains persistent problem there is no single algorithm the RRMM. Pomalidomide-based regimens are available in RRMM setting, with those that avoid re-use mAbs assuming greater importance following positioning these...
e23309 Background: BCMA-directed T-cell–engaging therapies have been introduced into clinical practice for the treatment of TCE RRMM. While efficacious, such treatments are associated with safety considerations as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), and serious infections. These also vary in reported efficacy, administration processes, hospitalization requirements. The aim this study is to quantify patient preferences tradeoffs regarding...
e23185 Background: Linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody, is being evaluated in LINKER-MM1, Phase 1/2 study patients with RRMM (NCT03761108). Early results over 36 weeks of treatment showed promising efficacy and generally manageable safety profile (Jagannath et al., ASH 2023), improvement or stability patient-reported outcomes (PROs) including pain fatigue (Hoffman 2023). We now report PRO data period 76 weeks. Methods: LINKER-MM1 who received the 5-25-200 mg...
e23310 Background: Chimeric antigen receptor T-cell therapy (CAR T) is FDA-approved in pts with triple-class exposed (TCE) relapsed/refractory (RR) MM after four or more prior lines of (LOTs). Real-world access to CAR T remains challenging due manufacturing capacity, financial barriers, and pt fitness. Pts certain pre-existing comorbidities (e.g., central nervous system disease, heart secondary malignancies) are commonly excluded from clinical trials, including those investigating T. The...
7560 Background: No head-to-head clinical trials have compared effectiveness of anti-BCMA×CD3 bispecific antibodies for TCE RRMM. This analysis efficacy linvoseltamab vs teclistamab via an unanchored matching-adjusted indirect comparison (MAIC). Methods: A MAIC was deemed feasible after excluding 10 patients (pts) with prior BCMA antibody–drug conjugate exposure from LINKER-MM1 (linvoseltamab) to match MajesTEC-1 (teclistamab) criteria. Pt-level data (107 pts receiving 200 mg in Phase 1/2,...
Statistical analysis• Baseline characteristics and treatment history for each cohort were summarized using descriptive statistics.• Median (95% CI) TTD, TTNT, OS estimated the Kaplan-Meier method cohort.• Cox proportional hazard models used to examine potential prognostic factors associated with in main cohort.Univariate assessed magnitude/ significance of baseline variables, known significant variables carried forward a multivariate model. ResultsPatient selection characteristics• In total,...
Background• Patients with metastatic basal cell carcinoma (mBCC) who are not candidates for surgery or radiation therapy generally treated hedgehog signaling pathway inhibitors (HHIs). 1 -However, intolerance and resistance to HHIs common. 1• Cemiplimab-rwlc is approved in the United States patients mBCC locally advanced BCC (laBCC) following HHI treatment whom appropriate. 2• In a Phase 2 clinical trial (NCT03132636), cemiplimab demonstrated an objective response rate of 24.1% (95% CI:...